Table 2 Univariate and multivariate Cox regression analyses of LDH and OS of patients with advanced pancreatic cancer in the training cohort.
Variable | Patients (n) | HR (95% CI) | p-value* |
|---|---|---|---|
Univariate analysis | |||
Sex (male vs. female) | 83 vs. 56 | 1.386 (0.903–2.129) | 0.135 |
Age (<60 vs. ≥60) | 54 vs. 85 | 0.947(0.623–1.441) | 0.8 |
Stage (III vs. IV) | 48 vs. 91 | 1.993 (1.244–3.194) | 0.004 |
Location (head vs. body/tail) | 62 vs. 77 | 0.805 (0.535–1.21) | 0.299 |
CA19-9 (<1000 vs. ≥1000 IU/mL) | 71 vs. 68 | 2.037 (1.344–3.088) | <0.001 |
LDH (<185 vs. ≥185 IU/mL) | 102 vs. 37 | 2.108 (1.329–3.346) | 0.002 |
KPS (<90 vs. ≥90) | 87 vs. 52 | 1.374 (0.891–2.118) | 0.151 |
Metastasis (Intrahepatic vs. Extrahepatic) | 74 vs. 17 | 0.648 (0.316–1.327) | 0.235 |
Location of intrahepatic metastasis (Left/Rirht Lobe vs. Left&Right Lobe) | 6 vs. 68 | 2.335 (0.718–7.592) | 0.159 |
Albumin (<38.6 vs. ≥38.6 g/L) | 55 vs. 84 | 0.817 (0.541–1.232) | 0.335 |
PLR (<154 vs. ≥154) | 84 vs. 55 | 1.104 (0.725–1.683) | 0.644 |
NLR (<3.42 vs. ≥3.42) | 93 vs. 46 | 2.522 (1.633–3.894) | <0.001 |
LMR (<3.19 vs. ≥3.19) | 72 vs. 67 | 0.497 (0.324–0.762) | 0.001 |
Multivariate analysis | |||
Stage (III vs. IV) | 48 vs. 91 | 1.623 (1.003–2.629) | 0.049 |
CA19-9 (<1000 vs. ≥1000 IU/mL) | 71 vs. 68 | 1.790 (1.159–2.764) | 0.009 |
LDH (<185 vs. ≥185 IU/mL) | 102 vs. 37 | 1.981 (1.226–3.200) | 0.005 |
NLR (<3.42 vs. ≥3.42) | 93 vs. 46 | 2.028(1.293–3.181) | 0.002 |
LMR(<3.19 vs. ≥3.19) | 72 vs. 67 | 0.883 (0.535–1.458) | 0.627 |
